| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Soros Fund Management · George Soros | $3.2M | 0.04% | 100.00K | — | Q2 2026 |
| Renaissance Technologies | $3.1M | 0.00% | 95.40K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AKTS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Czibere Akos M.D.Officer | Conversion of Exercise of derivative security at price 4.95 per share. | 12.5K | $61.88K |
| Sep 22, 2026 | Czibere Akos M.D.Officer | Sale at price 20.19 - 21.03 per share. | 12.5K | $258.62K |
| Jul 19, 2026 | Herrmann Ken M.D.Director | Conversion of Exercise of derivative security at price 0.08 - 1.91 per share. | 4.9K | $2.86K |
| Jul 19, 2026 | Herrmann Ken M.D.Director | Sale at price 24.56 per share. | 4.9K | $119.27K |
| Jul 16, 2026 | Herrmann Ken M.D.Director | Conversion of Exercise of derivative security at price 0.08 per share. | 3.1K | $245 |
| Jul 16, 2026 | Herrmann Ken M.D.Director | Sale at price 25.21 per share. | 3.1K | $77.26K |
| Jul 7, 2026 | Ron-Bigger Shulamit Ph.D.Chief Operating Officer | Conversion of Exercise of derivative security at price 3.66 per share. | 50K | $183.00K |
| Jul 7, 2026 | Czibere Akos M.D.Officer | Conversion of Exercise of derivative security at price 4.95 per share. | 50K | $247.50K |
| Jul 7, 2026 | Ron-Bigger Shulamit Ph.D.Chief Operating Officer | Sale at price 27.13 - 28.75 per share. | 50K | $1.39M |
| Jul 7, 2026 | Czibere Akos M.D.Officer | Sale at price 27.13 - 28.71 per share. | 50K | $1.39M |
| Jan 11, 2026 | Gadicke Ansbert S.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 1.11M | $20.03M |
| Jan 11, 2026 | Foley ToddDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 232.9K | $4.19M |
| Jan 11, 2026 | Kim Helen SusanDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 835K | $15.03M |
| Jan 11, 2026 | Mpm Bioventures 2018, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 1.11M | $20.03M |
| Jan 11, 2026 | Ecor1 Capital, L.L.C.Unknown | Purchase at price 18.00 per share. | 2.22M | $40.00M |
| Jan 11, 2026 | Vida Ventures Ii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 835K | $15.03M |
| Jan 11, 2026 | Gadicke Ansbert S.Beneficial Owner of more than 10% of a Class of Security | — | 8.81M | — |
| Jan 11, 2026 | Segal Lloyd MitchellDirector | — | 19.6K | — |
| Jan 11, 2026 | Foley ToddDirector and Beneficial Owner of more than 10% of a Class of Security | — | 4.00M | — |
| Jan 11, 2026 | Kim Helen SusanDirector and Beneficial Owner of more than 10% of a Class of Security | — | 4.99M | — |
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts